Trademark: 79093385
Word
TG THROMBOGENICS
Status
Dead
Status Code
709
Status Date
Friday, May 13, 2022
Serial Number
79093385
Registration Number
4047607
Registration Date
Tuesday, November 1, 2011
Mark Type
3000
Filing Date
Tuesday, November 30, 2010
Published for Opposition
Tuesday, August 16, 2011
Cancellation Date
Friday, May 13, 2022
Trademark Owner History
Oxurion NV - Original Registrant
ThromboGenics NV - Owner At Publication
Classifications
5 Pharmaceutical preparations for treatment of diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; veterinary preparations for treatment of diseases and disorders in mammalians, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; sanitary preparations for medical purposes; dietetic foods adapted for medical use, food for babies; medical plasters; material for stopping teeth, dental wax; disinfectants for medical instruments, for hygienic purposes, and for use in medical surgery procedures; preparations for destroying vermin; fungicides, herbicides; biopharmaceutical preparations, namely, anticoagulants, anti angiogenic drugs, anticancer drugs, cardiovascular drugs, protease enzymes, protease inhibitors, antibodies, plasmins, truncated plasmins, microplasmins, plasminogens, truncated plasminogens, microplasminogens, plasminogen activators, staphylokinases for the treatment diseases and disorders, namely, ophthalmic and visual disorders, vascular and cardiovascular disorders, cardiac diseases, stroke, inflammation, hypertension, pulmonary hypertension, edema, immune system disorders, immune system related disorders, eye diseases, blood disorders, thrombotic diseases and cancer; diagnostic medical reagents, chemicals and biological materials, namely, antigen and diagnostic kits consisting primarily of monoclonal and/or polyclonal antibodies, buffers, and reagents for medical laboratory use in disease testing
1 Chemical preparations and substances for use in the manufacture of pharmaceuticals
44 Medical services; veterinary services; medical, veterinary and pharmaceutical advisory and consultancy services; medical services, namely, therapeutic, prognostic and diagnostic testing services
42 Scientific and technological services, namely, scientific research and design of new products in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention, and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; industrial analysis and product research services in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder detection, in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder prevention and in the field of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer disease and disorder treatment; pharmaceutical, biopharmaceutical, medical, biomedical, biological, biochemical, toxicological and clinical research and product development of diagnostic tests and kits, biopharmaceutical preparations and drugs, and medicines; biopharmaceutical product evaluation; biological, biochemical, pharmaceutical, medical, toxicological and clinical research, scientific research for medical purposes in the treatment of ophthalmic, visual, vascular, cardiac, inflammation, hypertension, immune system, blood and cancer diseases and disorders; development services in the field of new biopharmaceutical drugs, preparations and medicines for ophthalmic, vascular and cancer pathologies
The mark consists of the letters "TG" in grey and the word "thrombogenics" in red with a grey vertical line separating the literal elements of the mark.
TG THROMBO GENICS
The color(s) red and grey is/are claimed as a feature of the mark.
"THROMBOGENICS"
Trademark Events
Apr 11, 2023
Total Invalidation Processed By The Ib
Mar 1, 2023
Total Invalidation Of Reg Ext Protection Sent To Ib
Mar 1, 2023
Invalidation Processed
Jan 13, 2023
Total Invalidation Of Reg Ext Protection Created
May 13, 2022
Cancelled Section 71
Dec 17, 2020
International Registration Renewed
Nov 1, 2020
Courtesy Reminder - Sec. 71 (10-Yr) E-Mailed
Jun 13, 2019
Change Of Name/Address Rec'd From Ib
Mar 8, 2019
Partial Invalidation Processed By The Ib
Jan 26, 2019
Partial Invalidation Of Reg Ext Protection Sent To Ib
Jan 26, 2019
Invalidation Processed
Jan 11, 2019
Partial Invalidation Of Reg Ext Protection Created
Sep 28, 2018
New Representative At Ib Received
May 11, 2018
Notice Of Acceptance Of Sec. 71 - E-Mailed
May 11, 2018
Registered - Partial Sec 71 Accepted
May 11, 2018
Case Assigned To Post Registration Paralegal
May 1, 2018
Teas Section 71 Received
Jul 28, 2012
Final Decision Transaction Processed By Ib
Jun 8, 2012
Final Disposition Notice Sent To Ib
Jun 8, 2012
Final Disposition Processed
Feb 1, 2012
Final Disposition Notice Created, To Be Sent To Ib
Nov 1, 2011
Registered-Principal Register
Aug 16, 2011
Published For Opposition
Jul 27, 2011
Notice Of Publication
Jul 13, 2011
Law Office Publication Review Completed
Jul 12, 2011
Assigned To Lie
Jun 18, 2011
Approved For Pub - Principal Register
Jun 17, 2011
Teas/Email Correspondence Entered
Jun 17, 2011
Correspondence Received In Law Office
Jun 17, 2011
Teas Response To Office Action Received
Apr 9, 2011
Refusal Processed By Ib
Mar 22, 2011
Non-Final Action Mailed - Refusal Sent To Ib
Mar 22, 2011
Refusal Processed By Mpu
Mar 19, 2011
Non-Final Action (Ib Refusal) Prepared For Review
Mar 18, 2011
Non-Final Action Written
Mar 12, 2011
Application Filing Receipt Mailed
Mar 8, 2011
Assigned To Examiner
Mar 8, 2011
New Application Office Supplied Data Entered
Mar 4, 2011
Limitation From Original Application Entered
Mar 3, 2011
Sn Assigned For Sect 66a Appl From Ib
TACTICAL INTERVENTION
N U F I B R A
Trademark Alertz updated from USPTO on 2030-01-24

Trademark Alertz ™ - GRJR PTY LTD 2024 - Privacy Policy - Terms of Use

The information provided on Trademark Alertz is not legal or professional advice. Information may have been obtained from third parties and may contain errors. You must make your own enquiries and seek independent advice from relevant industry professionals before acting or relying on any information from Trademark Alertz. All trade mark information has been obtained from and made publicly available by The United States Patent and Trademark Office (USPTO). Copyright of the trademark data resides with USPTO. www.uspto.gov